Quick Answer
Kiniksa Pharmaceuticals International, plc reported Research And Development Expense of $96.85 million for the year ending 2025.
- Kiniksa Pharmaceuticals International, plc showed a decrease of -13.2% in Research And Development Expense from 2024 to 2025.
- This data is from Kiniksa Pharmaceuticals International, plc's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Kiniksa Pharmaceuticals International, plc's Research And Development Expense has grown by 71.9%.
- Historical annual values: Fiscal year 2025: $96.85 million | Fiscal year 2024: $111.62 million | Fiscal year 2023: $76.10 million | Fiscal year 2022: $65.49 million | Fiscal year 2021: $99.30 million | Fiscal year 2020: $112.04 million | Fiscal year 2019: $135.00 million | Fiscal year 2018: $86.60 million | Fiscal year 2017: $56.36 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: